FibroGen Inc. (FGEN) CEO Thomas B. Neff Sells 18,899 Shares
FibroGen Inc. (NASDAQ:FGEN) CEO Thomas B. Neff sold 18,899 shares of the business’s stock in a transaction dated Tuesday, October 4th. The stock was sold at an average price of $20.67, for a total value of $390,642.33. Following the sale, the chief executive officer now owns 3,370,103 shares in the company, valued at approximately $69,660,029.01. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
FibroGen Inc. (NASDAQ:FGEN) opened at 20.73 on Thursday. FibroGen Inc. has a 1-year low of $14.38 and a 1-year high of $31.90. The stock’s market cap is $1.30 billion. The firm’s 50-day moving average price is $19.60 and its 200 day moving average price is $18.68.
FibroGen (NASDAQ:FGEN) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.36 by $0.01. FibroGen had a negative return on equity of 48.66% and a negative net margin of 61.90%. Equities research analysts expect that FibroGen Inc. will post ($1.25) EPS for the current year.
Separately, Credit Suisse Group AG reaffirmed a “buy” rating and set a $37.00 target price on shares of FibroGen in a research note on Tuesday, August 9th.
Institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC purchased a new position in FibroGen during the second quarter valued at about $106,000. Acrospire Investment Management LLC boosted its position in FibroGen by 240.2% in the second quarter. Acrospire Investment Management LLC now owns 6,657 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 4,700 shares in the last quarter. Teacher Retirement System of Texas boosted its position in FibroGen by 15.7% in the second quarter. Teacher Retirement System of Texas now owns 6,891 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 937 shares in the last quarter. Quantbot Technologies LP purchased a new position in FibroGen during the second quarter valued at about $164,000. Finally, Fox Run Management L.L.C. purchased a new position in FibroGen during the second quarter valued at about $176,000. Institutional investors and hedge funds own 49.82% of the company’s stock.
FibroGen Company Profile
FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Receive News & Stock Ratings for FibroGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc. and related stocks with our FREE daily email newsletter.